Entwicklung und Evaluierung neuer niedrig-molekularer Sonden für die Charakterisierung von Gefäßerkrankungen mittels der Magnetresonanztomographie

利用磁共振成像表征血管疾病的新型低分子探针的开发和评估

基本信息

批准号：
256670101
负责人：
Professor Dr. Marcus R. Makowski
金额：
--
依托单位：
Institut für diagnostische und interventionelle Radiologie
依托单位国家：
德国
项目类别：
Research Grants
财政年份：
2014
资助国家：
德国
起止时间：
2013-12-31 至 2021-12-31
项目状态：
已结题

来源：
https://gepris.dfg.de/gepris/projekt/256670101?language=en
关键词：
Entwicklung und Evaluierung neuer niedrig

项目摘要

Despite advances in diagnosis and treatment, cardiovascular diseases remain the leading cause of death in the western world. Atherosclerosis and aortic aneurysms are among the leading causes of mortality in industrialised and developing nations. The arterial vessel wall plays a crucial role in the onset and development of these pathologies. The prolonged course of subclinical and asymptomatic disease opens a diagnostic window before symptoms or life threatening complications can occur. This project investigates the hypothesis that the in vivo assessment of the arterial vessel wall on a molecular level will allow a biological characterisation of early pathological vessel wall changes and thereby improve the staging of vascular diseases and enable more accurate monitoring of therapy response. To achieve this aim, novel small molecular probes for detection with magnetic resonance imaging (MRI) will be developed and investigated in different disease models. Probes will first be characterised in vitro and in vivo concerning their binding and pharmacokinetic properties. Subsequently, the role of the targeted proteins during the development of atherosclerosis and aortic aneurysms will be investigated in vivo with these probes. The focus of this project will be on the evaluation of the usefulness of these probes for early disease detection, staging of disease development and monitoring of response to treatment.

尽管诊断和治疗方面取得了进步，但心血管疾病仍然是西方世界的主要死亡原因。动脉粥样硬化和主动脉瘤是工业化和发展中国家死亡的主要原因之一。动脉血管壁在这些病理的发作和发展中起着至关重要的作用。在症状或威胁生命并发症之前，亚临床和无症状疾病的长时间病程为诊断窗口打开。该项目调查了以下假设：分子水平上动脉血管壁的体内评估将允许对早期病理血管壁变化的生物学表征，从而改善血管疾病的分期，并可以更准确地监测治疗反应。为了实现这一目标，将在不同的疾病模型中开发和研究新的新型小分子探针（MRI）。探针将首先在体外和体内表征其结合和药代动力学特性。随后，将通过这些探针在体内研究靶蛋白在动脉粥样硬化和主动脉瘤发展过程中的作用。该项目的重点将放在评估这些探针对早期疾病检测，疾病发展和监测治疗反应的有用性上。